Akero First To Show Benefit In Cirrhotic NASH Patients

 
• By Joseph Haas
  
3D illustration of many arrows symbols pointing in the same direction and one arrow going back. Concept of regression.
In a small sample, Akero's EFX showed an ability to reverse cirrhosis in NASH patients
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D